Agilon Health (NYSE:AGL) Stock Price Expected to Rise, Benchmark Analyst Says

Agilon Health (NYSE:AGL) had its price target lifted by Benchmark from $1.50 to $13.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Benchmark’s target price would suggest a potential upside of 25.00% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. BTIG Research reiterated a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st. Barclays dropped their target price on shares of Agilon Health from $25.00 to $12.50 and set an “underweight” rating on the stock in a research report on Friday, February 27th. Royal Bank Of Canada upgraded shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Finally, Citigroup decreased their price target on shares of Agilon Health from $21.25 to $18.75 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Three research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $51.93.

Agilon Health Price Performance

Shares of AGL traded up $0.65 during trading hours on Thursday, reaching $10.40. The stock had a trading volume of 164,916 shares, compared to its average volume of 272,767. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02. Agilon Health has a 12 month low of $7.48 and a 12 month high of $152.00. The stock has a market capitalization of $172.59 million, a PE ratio of -0.44 and a beta of 0.33. The company’s 50-day moving average is $14.26 and its two-hundred day moving average is $18.59.

Agilon Health (NYSE:AGL) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative net margin of 6.60% and a negative return on equity of 120.82%. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.46 billion. Research analysts expect that Agilon Health will post -0.59 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

Several hedge funds and other institutional investors have recently made changes to their positions in AGL. Wealthcare Advisory Partners LLC bought a new position in shares of Agilon Health in the third quarter valued at approximately $26,000. LPL Financial LLC lifted its holdings in Agilon Health by 213.4% during the fourth quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock worth $30,000 after acquiring an additional 30,000 shares during the period. Krilogy Financial LLC purchased a new position in Agilon Health in the fourth quarter worth $34,000. CIBC Bancorp USA Inc. purchased a new position in Agilon Health in the third quarter worth $34,000. Finally, Merit Financial Group LLC bought a new position in Agilon Health in the 4th quarter valued at $35,000.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.